Toxicity associated to efavirenz in HIV-infected persons enrolled in an expanded acces program;Toxicidad asociada a efavirenz en personas infectadas por el VIH incluidas en el programa de acceso expandido

Medicina Clinica

Volumn 115, Issue 9, 2000, Pages 337-338

  Dona, Carmen ^a   Soriano, Vicenç ^a   Barreiro, Pablo ^a   Jiménez Nácher, Inmaculada ^a   González Lahoz, Juan ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Adverse effects; Antiretroviral drugs; Efavirenz; HIV; Toxicity

Indexed keywords

EFAVIRENZ;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NEUROLOGIC DISEASE; SCORING SYSTEM; SKIN DEFECT; WORLD HEALTH ORGANIZATION;

EID: 0034706151     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7753(00)71549-1     Document Type: Article

References (10)

1. Efavirenz
2. A randomized double-blind trial comparing combinations of nevirapine, didanosine and zidovudine for HIV-1 infected patients: The INCAS Trial
3. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
4. Reversion of metabolic abnormalities after swithching from HIV-1 protease inhibitors to nevirapine
5. Efavirenz in the management of HIV infection
6. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy
7. Redestribution of body fat in HIV-infected women undergoing combined antiretroviral therapy
8. Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue
9. Higher antiviral activity of antiretroviral regimens including protease inhibitors